ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)

TYO:4886 Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	6,859	10,126	10,603	13,738	14,505	12,103
Short-Term Investments	-	893	555	3,500	3,400	5,000
Cash & Short-Term Investments	6,859	11,019	11,158	17,238	17,905	17,103
Cash Growth	-7.91%	-1.25%	-35.27%	-3.72%	4.69%	62.67%
Receivables	18,375	15,955	15,090	15,579	15,217	14,482
Inventory	28,535	29,181	26,333	20,402	17,687	15,060
Other Current Assets	4,668	5,269	5,466	2,924	2,950	2,912
Total Current Assets	58,437	61,424	58,047	56,143	53,759	49,557
Property, Plant & Equipment	19,102	19,244	18,709	11,263	10,796	10,936
Long-Term Investments	21,483	20,756	14,472	17,765	16,400	14,244
Goodwill	2,354	2,354	4,361	-	-	-
Other Intangible Assets	6,149	6,515	2,632	2,877	4,465	6,183
Long-Term Deferred Tax Assets	1,144	2,085	2,312	2,696	1,717	2,376
Other Long-Term Assets	3,213	1	1	1	1	1
Total Assets	111,882	112,379	100,534	90,745	87,138	83,297

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	6,703	7,558	9,146	7,355	5,860	6,841
Accrued Expenses	-	1,316	1,283	1,225	1,166	1,188
Short-Term Debt	2,520	1,707	2,521	300	300	300
Current Portion of Long-Term Debt	-	1,562	1,940	4,680	3,138	1,423
Current Income Taxes Payable	-	8,020	6,367	8,690	4,947	4,867
Other Current Liabilities	10,016	2,128	1,622	1,718	2,239	1,392
Total Current Liabilities	19,239	22,291	22,879	23,968	17,650	16,011
Long-Term Debt	7,394	8,165	6,441	4,505	9,185	12,323
Pension & Post-Retirement Benefits	22	23	206	-	5,433	5,730
Other Long-Term Liabilities	5,004	5,081	1,813	343	337	341
Total Liabilities	31,659	35,560	31,339	28,816	32,605	34,405

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1,197	1,197	1,197	1,197	1,197	1,197
Additional Paid-In Capital	-	31	-	1,848	1,847	1,867
Retained Earnings	64,360	63,352	59,545	56,372	49,619	45,833
Treasury Stock	-583	-658	-704	-3,287	-3,350	-3,479
Comprehensive Income & Other	8,380	6,438	5,272	5,799	5,220	3,474
Total Common Equity	73,354	70,360	65,310	61,929	54,533	48,892
Minority Interest	6,869	6,459	3,885	-	-	-
Shareholders' Equity	80,223	76,819	69,195	61,929	54,533	48,892
Total Liabilities & Equity	111,882	112,379	100,534	90,745	87,138	83,297

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	9,914	11,434	10,902	9,485	12,623	14,046
Net Cash (Debt)	-3,055	-415	256	7,753	5,282	3,057
Net Cash Growth	-	-	-96.70%	46.78%	72.78%	-
Net Cash Per Share	-107.38	-14.62	9.03	273.83	187.05	107.75
Filing Date Shares Outstanding	28.45	28.4	28.36	28.33	28.29	28.18
Total Common Shares Outstanding	28.45	28.4	28.36	28.33	28.29	28.18
Working Capital	39,198	39,133	35,168	32,175	36,109	33,546
Book Value Per Share	2578.37	2477.80	2302.59	2186.05	1927.97	1734.75
Tangible Book Value	64,851	61,491	58,317	59,052	50,068	42,709
Tangible Book Value Per Share	2279.50	2165.47	2056.04	2084.49	1770.12	1515.37

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error